home / stock / nnvc / nnvc quote
Last: | $1.10 |
---|---|
Change Percent: | -1.28% |
Open: | $1.19 |
Close: | $1.10 |
High: | $1.19 |
Low: | $1.09 |
Volume: | 22,323 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.1 | $1.19 | $1.1 | $1.19 | $1.09 | 22,323 | 04-19-2024 |
$1.175 | $1.15 | $1.175 | $1.2075 | $1.15 | 13,093 | 04-18-2024 |
$1.16 | $1.18 | $1.16 | $1.23 | $1.15 | 7,733 | 04-17-2024 |
$1.18 | $1.17 | $1.18 | $1.2232 | $1.17 | 8,623 | 04-16-2024 |
$1.15 | $1.2501 | $1.15 | $1.29 | $1.13 | 75,187 | 04-15-2024 |
$1.25 | $1.295 | $1.25 | $1.3362 | $1.25 | 13,594 | 04-12-2024 |
$1.27 | $1.36 | $1.27 | $1.36 | $1.25 | 24,617 | 04-11-2024 |
$1.31 | $1.35 | $1.31 | $1.41 | $1.28 | 32,554 | 04-10-2024 |
$1.36 | $1.41 | $1.36 | $1.45 | $1.34 | 16,711 | 04-09-2024 |
$1.39 | $1.34 | $1.39 | $1.42 | $1.3204 | 35,541 | 04-08-2024 |
$1.37 | $1.38 | $1.37 | $1.48 | $1.31 | 65,517 | 04-05-2024 |
$1.37 | $1.29 | $1.37 | $1.5 | $1.2651 | 159,443 | 04-04-2024 |
$1.28 | $1.24 | $1.28 | $1.28 | $1.2218 | 10,211 | 04-03-2024 |
$1.27 | $1.19 | $1.27 | $1.3 | $1.19 | 38,355 | 04-02-2024 |
$1.3 | $1.15 | $1.3 | $1.36 | $1.14 | 121,239 | 04-01-2024 |
$1.16 | $1.12 | $1.16 | $1.175 | $1.12 | 23,191 | 03-29-2024 |
$1.16 | $1.12 | $1.16 | $1.175 | $1.12 | 23,191 | 03-28-2024 |
$1.13 | $1.13 | $1.13 | $1.135 | $1.12 | 6,335 | 03-27-2024 |
$1.14 | $1.12 | $1.14 | $1.14 | $1.11 | 15,268 | 03-26-2024 |
$1.13 | $1.13 | $1.13 | $1.16 | $1.12 | 18,592 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 o...
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial...